Antler Bio

The dairy and livestock sector has long struggled to align its key metrics of animal welfare, sustainability, and productivity. It has traditionally relied upon standard tools which provide limited data—and often after the damage occurs. Antler Bio has changed the game in an unparalleled way—with epigenetics-based livestock monitoring, giving farmers information to make proactive choices to support healthy, productive herds.

Co-founded in 2020 by Maria Jensen and Nathalie Conte, Antler Bio was born from the intersection of biotechnology and agriculture. Its flagship product, EpiHERD, is the world's first gene expression analytics platform for dairy cattle. Rather than relying on limits on static genetic testing, it measures RNA markers through simple blood tests to see how factors including stress, nutrition, and the environment affect an animal's productivity in real-time. Antler Bio garnered interest as soon as it was launched, for actual outcomes that were more impactful than mere theoretical science. For instance, on-farm EpiHERD trials have shown increases in milk yield by 22%, increased milk fat % by 6%, and increased protein % by 5%. EpiHERD farmers are provided with custom dashboards and benchmarking tools to provide meaningful insight from complex epigenetic data and deliver simple, actionable recommendations. Antler Bio essentially turns biology into a practical reality for today's farmers, from nutrient deficiencies to illness forecasting.

Antler Bio utilizes a hybrid subscription and pay-per-analysis pricing model that allows its EpiHERD platform to be used by farms of all shapes and sizes. Clients typically pay a monthly or quarterly retainer fee that depends on herd size and pay per test for each blood sample analyzed. This structure allows users to maintain an affordable presence on a small farm while having the option to pay more according to usage on a commercial operation. Their revenue is driven primarily by recurring SaaS revenue, with diagnostic service fees providing a secondary source. Antler Bio's revenue generation supports predictable revenues and therefore long-term profitability - by having increased usage and high ROI for farmers is a proven formula for a profitable business.

With strong investor support, the firm has raised $8.5 million of total capital over time including a $4.3 million seed round in 2025 led by The First Thirty Ventures, along with Endgame Capital and Generation-RE, which is an investment syndicate focused on regenerative agriculture. The purpose of these funds was to grow the platform, bolster R&D and speed up geographic growth. Antler Bio's revenue model is based on a subscription SaaS model and pay-per-test diagnostics based on the herd size; therefore the product is re-priced to be affordable for small family farms as well as large scale dairies. While the company has not publicly released complete financial statements, estimates derived from scale of deployment and direct pricing indicate annual revenue estimates in the mid-seven figures (approximately $5 – $7 million in 2024). Based on rising adoption and operational discipline, we believe the firm reached break-even by Q2 2025, an important milestone that is indicative of both great market interest and managing costs effectively.

Antler Bio has continued to make strong advances, both in respect to growing its team and expanding its market. The company currently employs 32 people across its science, product, and commercial teams. Although they are currently headquartered in Ireland, they have rolled out their platform across farms in Ireland, the UK, Sweden, Denmark, and Finland, and are now beginning to expand into Germany, the Netherlands, and North America. The company has made a lot of gains in regional penetration by forming strategic partnerships with leading dairy co-operatives and research institutions, particularly in Scandinavia. 

With competitors, including SomaDetect, Allflex, CattleEye, Connecterra, and ZELP, there continues to be only one company that is commercializing epigenetics at the scale they offer for livestock. A comparison of Antler Bio's offering to that of its competitors illustrates the unique competitive position of the firm. Although competitors offer visual or behavioral analytics, the company’s EpiHERD platform provides farmers continuous solutions that go well beyond merely reacting to observable and visible symptoms. EpiHERD enables farmers to detect stress, illness, and inefficiency at the molecular level, long before a decline in performance is observable. Thus, farmers with EpiHERD may at least be aware of areas that require corrective action much earlier and, therefore, realize the associated benefits. With an already established technology, the firm has an early advantage in the agri-tech landscape.

Looking ahead, the company is set to market not only cattle, but will be looking to enter poultry and swine as well. They are also interested in further integrating climate monitoring, feed optimization, and other farm technologies to offer a more full-stack livestock intelligence product. To quote co-founder Maria Jensen: “We believe the solutions to the largest challenges of food production lie in biology. Our goal is to unlock that biology agnostic of end users, enabling farmers to make smarter and more sustainable decisions, herd by herd." With a distinctive scientific methodology, solid funding, operational profitability, and a growing multinational footprint, Antler Bio is rapidly becoming one of the most innovative firms in agricultural biotechnology. As the industry migrates to a precision and sustainable orientation, Antler Bio is defining the evolution, not just following.

Click here to access Antler Bio's website.